Seegene (KSDQ:096530) said today that it inked a collaboration deal with Hologic (NSDQ:HOLX) to develop high-multiplex, real-time PCR reagents for the developing Hologic Panther Fusion system.
According to the agreement, Seegene will develop and manufacture multiplex assays for Hologic’s next-gen molecular diagnostics platform; Hologic will receive worldwide commercialization rights to the assays. Financial terms of the deal were not disclosed.
Get the full story at our sister site, Drug Delivery Business News.